Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.91% Nasdaq Up0.87%

Valeant Pharmaceuticals International, Inc. (VRX)

-NYSE

85.86 Up 1.04(1.23%) 4:03PM EDT|After Hours : 86.93 Up 1.07 (1.24%) 5:03PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingMar 30, 2013Dec 30, 2012Sep 29, 2012Jun 29, 2012
Total Revenue 1,068,355   986,293   884,140   820,090  
Cost of Revenue300,333  286,661  230,252  209,767  
Gross Profit 768,022   699,632   653,888   610,323  
Operating Expenses
Research Development23,795  20,165  19,170  17,711  
Selling General and Administrative239,714  176,233  194,290  193,169  
Non Recurring61,332  301,834  192,777  102,063  
Others326,175  299,485  218,187  210,570  
Total Operating Expenses651,016  797,717  624,424  523,513  
Operating Income or Loss 117,006   (98,085) 29,464   86,810  
Income from Continuing Operations
Total Other Income/Expenses Net(16,485)(21,843)(2,769)(3,253)
Earnings Before Interest And Taxes100,521  (119,928)26,695  83,557  
Interest Expense155,315  154,715  116,042  100,614  
Income Before Tax(54,794)(274,643)(89,347)(17,057)
Income Tax Expense(27,264)(185,501)(96,992)4,550  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(48,909)(106,767)5,323  (21,607)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (27,530) (89,142) 7,645   (21,607)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (27,530) (89,142) 7,645   (21,607)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.